search
Back to results

Botulinum Toxin A in Patients With Myofascial Pain Syndrome With and Without Zinc Supplementation

Primary Purpose

Myofacial Pain Syndrome, Botulinum Toxin

Status
Enrolling by invitation
Phase
Early Phase 1
Locations
Egypt
Study Type
Interventional
Intervention
Solvazinc 50mg
placebo
Sponsored by
Cairo University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myofacial Pain Syndrome

Eligibility Criteria

17 Years - 50 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Patients with myofascial pain Both genders males and females will be included. Ages from 17:50 Y General good health With complete dentation Exclusion Criteria: Subjected to irradiation in the head and neck area less than 1 year ago Edentulous patients Patient with recent trauma. Poor motivation. Active infection area related to masseter or temporalis. Patient with anti-tetanus vaccine 1-3 m before experiment

Sites / Locations

  • Faculty of Dentistry

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

first group: (Control group)

second group. (intervention group)

Arm Description

EMG will be performed for masseter & temporalis muscles at the diagnosis appointment. Patients will recieve a daily placebo tablet in the morning after breakfast for 4 days prior to injections. Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis). Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection.

EMG will be performed for masseter & temporalis muscles at the diagnosis appointment. Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections. Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis). Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection.

Outcomes

Primary Outcome Measures

Muscular Activity
will be assessed by EMG
Pressure Pain Threshold (PPT)
will be assessed by algometer

Secondary Outcome Measures

Full Information

First Posted
September 29, 2022
Last Updated
February 6, 2023
Sponsor
Cairo University
search

1. Study Identification

Unique Protocol Identification Number
NCT05605886
Brief Title
Botulinum Toxin A in Patients With Myofascial Pain Syndrome With and Without Zinc Supplementation
Official Title
The Effect of Botulinum Toxin A in Patients With Myofascial Pain Dysfunction Syndrome With and Without Zinc Supplementation (Randomized Controlled Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
May 20, 2022 (Actual)
Primary Completion Date
April 20, 2023 (Anticipated)
Study Completion Date
May 20, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Research question: Dose the use of oral zinc supplement improve the effects of botulinum toxins injection in patients with myofascial pain dysfunction syndrome? Statement of the problem: MPDS Patients treated with botulinum toxin A injection usually suffers from return of the symptoms which requires successive injections almost every (3-4M) Rationale for conducting the research: The concept of adding the zinc supplementation prior to BTXA injection is contributed to the fact that botulinum toxin is a zinc-dependent metalloprotease; therefore, every botulinum toxin molecule must be accompanied with a zinc molecule to effectively paralyze a muscle. However, commercially available BTXA preparations exclude zinc from their preparations, and BTX clinical efficiency and duration varies according to the zinc levels of the patient. Although the BTX effect could remain for several months, its zinc-dependent proteolytic activity befalls within hours of administration before the toxins are degraded in the tissues. Therefore, for achieving better results from BTX, the recipients should have adequate zinc levels at the time of administration. Therefore, oral zinc supplement intake prior to BTXA injection may enhance its clinical efficiency and duration. botulinum neurotoxins are the most potent toxins known. They bind to nerve cells, penetrate the cytosol and block neurotransmitter release. Comparison of their predicted amino acid sequences reveals a highly conserved segment that contains the HExxH zinc binding motif of metalloendo peptidases. The metal content of tetanus toxin was then measured and it was found that one atom of zinc is bound to the light chain of tetanus toxin. Zinc could be reversibly removed by incubation with heavy metal chelators. Zn2+ is coordinated by two histidines with no involvement in cysteines, suggesting that it plays a catalytic rather than a structural role. Bound Zn + was found to be essential for the tetanus toxin inhibition of neurotransmitter release in Aplysia neurons injected with the light chain. The intracellular activity of the toxin was blocked by phosphoramidon, a very specific inhibitor of zinc endopeptidases. Purified preparations of light chain showed a highly specific proteolytic activity against synaptobrevin, an integral membrane protein of small synaptic vesicles. The present findings indicate that tetanus toxin, and possibly also the botulinum neurotoxins, are metalloproteases and that they block neurotransmitter release via this protease activity. So The use of zinc supplementation prior to BTXA injection has been suggested by several previous studies to prolong its duration of action as well as improve its efficacy
Detailed Description
Myofascial pain syndrome is a complex disorder of the musculoskeletal system with multifactorial involvement and diverse clinical presentations in several areas of the body It can affect the oro-cranio-facial region, with involvement of the temporomandibular area and masticatory muscles, and is then called myofascial pain dysfunction syndrome. Botulinum injections can improve blood flow to the muscles and release the nerve fibers compressed by abnormally contracting muscles, both of which may contribute to the cause of pain. In addition, botulinum injections can have an immediate effect owing to direct release of endogenous endorphins from introduction of the needle and alteration in the balance of central neurotransmitters; this is caused by local inhibition of pain peptides from sensory ganglions and nerve terminals, and anti-inflammatory and antiglutaminergic actions . Moreover, studies have shown that 3-10% of patients develop neutralizing antibodies with long-term adverse effects that include muscular atrophy. BTX clinical efficiency and duration varies according to the zinc levels of the patient. Although the BTX effect could remain for several months, its zinc-dependent proteolytic activity befalls within hours of administration before the toxins are degraded in the tissues. Therefore, for achieving better results from BTX, the recipients should have adequate zinc levels at the time of administration. Therefore, oral zinc supplement intake prior to BTXA injection may enhance its clinical efficiency and duration. Explanation for choice of comparators: BTX is offered as a solution for myofascial pain patients; nevertheless, it is not considered as a definitive long-term solution so we add the zinc supplementation prior to BTXA injection to increase the clinical duration as reviewed in literature review.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myofacial Pain Syndrome, Botulinum Toxin

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Model Description
All patients involved in this study will be divided in to two different groups, one group will undergo zinc supplement then botulinum toxins injection in masseter and temporalis muscle while the other group will have botulinum toxins injection in masseter and temporalis muscle without previous zinc supplement
Masking
ParticipantOutcomes Assessor
Masking Description
2 Cards will have sequential numbers one number for each card then these cards will be placed within opaque sealed envelopes. Then these envelops will be placed in a container (box), each participant will grasp one envelop the day of procedure
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
first group: (Control group)
Arm Type
Placebo Comparator
Arm Description
EMG will be performed for masseter & temporalis muscles at the diagnosis appointment. Patients will recieve a daily placebo tablet in the morning after breakfast for 4 days prior to injections. Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis). Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection.
Arm Title
second group. (intervention group)
Arm Type
Active Comparator
Arm Description
EMG will be performed for masseter & temporalis muscles at the diagnosis appointment. Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections. Patients will receive a one-time treatment of 50 units of BoNT-A, the dose will be injected into the bilateral masseter muscles (16.7 units each masseter) and 1/3 into the bilateral temporalis (8.3 units each temporalis). Follow up will be performed using EMG for the masseter and temporalis muscles 4 months after the BoNT-A injection.
Intervention Type
Drug
Intervention Name(s)
Solvazinc 50mg
Other Intervention Name(s)
zinc supplement
Intervention Description
Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo
Primary Outcome Measure Information:
Title
Muscular Activity
Description
will be assessed by EMG
Time Frame
4 months
Title
Pressure Pain Threshold (PPT)
Description
will be assessed by algometer
Time Frame
4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
17 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients with myofascial pain Both genders males and females will be included. Ages from 17:50 Y General good health With complete dentation Exclusion Criteria: Subjected to irradiation in the head and neck area less than 1 year ago Edentulous patients Patient with recent trauma. Poor motivation. Active infection area related to masseter or temporalis. Patient with anti-tetanus vaccine 1-3 m before experiment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nadia Galal
Organizational Affiliation
professor
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Omnia Adel aziz
Organizational Affiliation
professor
Official's Role
Study Director
Facility Information:
Facility Name
Faculty of Dentistry
City
Cairo
State/Province
Manial
ZIP/Postal Code
67845
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25105993
Citation
Cohen JL. Scientific skepticism and new discoveries: an analysis of a report of zinc/phytase supplementation and the efficacy of botulinum toxins in treating cosmetic facial rhytides, hemifacial spasm and benign essential blepharospasm. J Cosmet Laser Ther. 2014 Oct;16(5):258-62. doi: 10.3109/14764172.2014.948882. Epub 2014 Sep 2.
Results Reference
background
PubMed Identifier
22069621
Citation
Lebeda FJ, Cer RZ, Mudunuri U, Stephens R, Singh BR, Adler M. The zinc-dependent protease activity of the botulinum neurotoxins. Toxins (Basel). 2010 May;2(5):978-97. doi: 10.3390/toxins2050978. Epub 2010 May 7.
Results Reference
background
PubMed Identifier
1396558
Citation
Schiavo G, Poulain B, Rossetto O, Benfenati F, Tauc L, Montecucco C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J. 1992 Oct;11(10):3577-83. doi: 10.1002/j.1460-2075.1992.tb05441.x.
Results Reference
background
PubMed Identifier
34105695
Citation
DE LA Torre Canales G, Camara-Souza MB, Poluha RL, Grillo CM, Conti PCR, Sousa MDLR, Rodrigues Garcia RCM, Rizzatti-Barbosa CM. Botulinum toxin type A and acupuncture for masticatory myofascial pain: a randomized clinical trial. J Appl Oral Sci. 2021 Jun 4;29:e20201035. doi: 10.1590/1678-7757-2020-1035. eCollection 2021.
Results Reference
background

Learn more about this trial

Botulinum Toxin A in Patients With Myofascial Pain Syndrome With and Without Zinc Supplementation

We'll reach out to this number within 24 hrs